natgillin/translations-raw huggingface dataset:
Bevacizumab er, i kombination med platinbaseret kemoterapi, indiceret til 1.-linjebehandling af voksne patienter med ikke-operabel fremskreden, metastatisk eller recidiverende, ikke-småcellet lungekræft. 
Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.
69 % af patienterne i de 2 behandlingsarme havde serøs histologisk type af adenokarcinom. 
The incidence of each histologic sub-type of EOC was similar between the treatment arms; 69% of patients in each treatment arm had serous adenocarcinoma histologic type.
• Carboplatin (AUC4, dag 1) og gemcitabin (1.000 mg/m2 på dag 1 og 8) samtidig med placebo hver 3. uge i 6 og op til 10 behandlingsserier, efterfulgt af placebo (hver 3. uge) som monoterapi indtil sygdomsprogresssion eller uacceptabel toksicitet. 
A total of 484 patients with measurable disease were randomised 1:1 to either: • Carboplatin (AUC4, Day 1) and gemcitabine (1000 mg/m2 on Days 1 and 8) and concurrent placebo every 3 weeks for 6 and up to 10 cycles followed by placebo (every 3 weeks) alone until disease progression or unacceptable toxicity
Hvert 16 ml hætteglas indeholder 400 mg bevacizumab svarende til 16,5 mg/ml efter foreskreven fortynding. 
Each 16 ml vial contains 400 mg of bevacizumab, corresponding to 16.5 mg/ml when diluted as recommended
Progressionsfri overlevelse Median tid (måneder) Hazard ratio p-værdi 
Progression-free survival Median time (months) Hazard ratio p-value
Ved forskellige indikationer er der set fistler, der involverer andre dele af kroppen end mavetarmkanalen (f.eks. bronkopleurale og biliære fistler). 
Uncommon (≥ 0.1% to < 1%) reports of fistulae that involve areas of the body other than the gastrointestinal tract (e.g. bronchopleural and biliary fistulae) were observed across various indications.
I et klinisk studie hos patienter med persisterende, recidiverende eller metastatisk cervixcancer (studie GOG-0240) blev infektioner af grad 3-5 rapporteret hos op til 24 % af patienterne, behandlet med Avastin i kombination med paclitaxel og topotecan, sammenlignet med hos op til 13 % af patienterne, behandlet med paclitaxel og topotecan. 
From a clinical trial in patients with persistent, recurrent, or metastatic cervical cancer (study GOG0240), grade 3-5 infections have been reported in up to 24% of patients treated with Avastin in combination with paclitaxel and topotecan compared with up to 13% of patients treated with paclitaxel and topotecan.
(p-værdi = 0,00004) 
(p-value = 0.00004)
I et klinisk studie hos patienter med persisterende, recidiverende eller metastatisk cervixcancer (studie GOG-0240) blev blødninger af grad 3-5 rapporteret hos op til 8,3 % af patienterne, som blev behandlet med Avastin i kombination med paclitaxel og topotecan, sammenlignet med hos op til 4,6 % af patienterne, som blev behandlet med paclitaxel og topotecan. 
From a clinical trial in patients with persistent, recurrent, or metastatic cervical cancer (study GOG0240), grade 3-5 bleeding reactions have been reported in up to 8.3% of patients treated with Avastin in combination with paclitaxel and topotecan compared with up to 4.6% of patients treated with paclitaxel and topotecan.
I et klinisk studie hos patienter med persisterende, recidiverende eller metastatisk cervixcancer (studie GOG-0240) blev venøs tromboemboli af grad 3-5 rapporteret hos op til 15,6 % af patienterne, som blev behandlet med Avastin i kombination med paclitaxel og cisplatin, sammenlignet med hos op til 7,0 % af patienterne, som blev behandlet med paclitaxel og cisplatin. 
From a clinical trial in patients with persistent, recurrent, or metastatic cervical cancer (study GOG0240), grade 3-5 venous thromboembolic events have been reported in up to 15.6% of patients treated with Avastin in combination with paclitaxel and cisplatin compared with up to 7.0% of patients treated with paclitaxel and cisplatin.
I studie BO25041 blev Avastin føjet til post-operativ strålebehandling med samtidig adjuverende temozolomidbehandling hos pædiatriske patienter med nyligt diagnosticeret supratentorielt, infratentorielt, cerebellært eller pedunkulært høj-grads-gliom. 
In study BO25041 of Avastin added to postoperative radiation therapy (RT) with concomitant and adjuvant temozolomide in paediatric patients with newly diagnosed supratentorial, infratentorial, cerebellar, or peduncular high-grade glioma, the safety profile was comparable with that observed in other tumour types in adults treated with Avastin.
1 Hos patienter med målbar sygdom ved baseline. 
5 Patients with measurable disease at baseline.
• CPP-arm: Fem serier af placebo (startende i serie 2) i kombination med carboplatin (AUC 6) og paclitaxel (175 mg/m2) i 6 serier, efterfulgt af placebo alene, i op til sammenlagt 15 måneders behandling 
• CPP arm: Five cycles of placebo (started cycle 2) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m2) for 6 cycles followed by placebo alone, for a total of up to 15 months of therapy
• søvnighed, 
• sleepiness,
• nedsat antal af celler i blodet, inklusive hvide blodlegemer som hjælper med at bekæmpe infektioner i kroppen (kan være ledsaget af feber) og celler, der hjælper blodet med at størkne, 
• decreased number of cells in the blood, including white cells that help to fight against infections
6.6. for anbefaling om fortynding og anden håndtering. 
For dilution and other handling recommendations, see section 6.6.
Fistlera,b Myalgi Artralgi Muskelsvaghed Rygsmerter 
Myalgia, Arthralgia, Muscular weakness, Back Pain
(p-værdi = 0,0062) 
(p-value = 0.0062)
• blokering af blodårerne i lungerne på grund af en blodprop, 
• blocking of the blood vessels of the lungs by a blood clot,
Hvert 4 ml hætteglas indeholder 100 mg bevacizumab. 
Each 4 ml vial contains 100 mg of bevacizumab.
Antallet af infusioner, som du skal have, afhænger af, hvordan du reagerer på behandlingen. 
The number of infusions that you receive will depend on how you are responding to treatment; you should continue to receive this medicine until Avastin fails to stop your tumour growing.
Proteinuri (se pkt. 
Proteinuria (see section 4.8)
Lægemidlet må kun udleveres efter ordination på en recept udstedt af en begrænset lægegruppe (se bilag I: Produktresumé; pkt. 
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex: Summary of Product Characteristics, section 4.2).
• en blodprop i lungerne, 
● a blood clot in the blood vessels of your lungs,
Pulmonal blødning/ hæmoptysea,b Lungeemboli Epistaxis Dyspnø Hypoksi 
Pulmonary embolism, Hypoxia, Dysphoniaa
Antal patienter Samlet overlevelse Median (måneder) Hazard ratio 
Number of patients Overall survival Median (months) Hazard ratio
samtidig med Avastin (15 mg/kg) hver 3. uge i 6 og op til 8 behandlingsserier, efterfulgt af Avastin (15 mg/kg hver 3. uge) som monoterapi indtil sygdomsprogresssion eller uacceptabel toksicitet. 
Avastin (15 mg/kg Day 1) every 3 weeks for 6 and up to 10 cycles followed by Avastin (15 mg/kg every 3 weeks) alone until disease progression or unacceptable toxicity
Studiet var et randomiseret, dobbeltblindet, aktivt kontrolleret, klinisk fase III-studie, som evaluerede Avastin i kombination med IFL som 1.-linjebehandling af metastatisk kolorektalkræft. 
This was a phase III randomised, double-blind, active-controlled clinical trial evaluating Avastin in combination with IFL as first-line treatment for metastatic carcinoma of the colon or rectum.
Ingen klinisk betydningsfuld fordel i PFS blev observeret hos patienter, som kun fik bevacizumab i kombination med kemoterapi og ikke fortsatte med at få bevacizumab-monoterapi (CPB15). 
In patients who only received bevacizumab in combination with chemotherapy and did not continue to receive bevacizumab alone (CPB15), no clinically meaningful benefit in PFS was observed.
Hazard ratio (95% konfidensinterval) (registrerings-form)b p-værdi 
p-Value Hazard ratio (95% CI) (registration form)b
Trombo emboli (arteriel)a,b 
Thromboembolism arteriala,b, Haemorrhage a,b
Galde-blæreperfora tiona,b 
Gallbladder perforationa,b
Gastrointestinale forstyrrelser Proktalgi 
Gastrointestinal disorders
• CPB15-arm: Fem serier af Avastin (15 mg/kg hver 3. uge startende i serie 2) i kombination med carboplatin (AUC 6) og paclitaxel (175 mg/m2) i 6 serier, efterfulgt af placebo alene, i op til sammenlagt 15 måneders behandling 
• CPB15 arm: Five cycles of Avastin (15 mg/kg q3w started cycle 2) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m2) for 6 cycles followed by placebo alone, for a total of up to 15 months of therapy
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hvert hætteglas indeholder 100 mg bevacizumab. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains 100 mg bevacizumab.
Resultater fra en eksplorativ analyse af samlet overlevelse, som inkluderer yderligere 7 måneders opfølgning (ca. 46 % af patienterne var døde), er også præsenteret. 
The results of this study from the final protocol defined analyses for progression free survival and response rates for the independently powered capecitabine cohort of Study AVF3694g are presented in Table 11 Results from an exploratory overall survival analysis which include an additional 7 months of follow-up (approximately 46% of patients had died) are also presented.
• Avastin-armene var bedre med hensyn til progressionsfri overlevelse i ITT (intent-to-treat) populationen (tabel 7) i forhold til behandlingsarmene, der kun indeholdt kemoterapi. 
● Superiority of the Avastin-containing arms versus the chemotherapy alone arms in the overall comparison was demonstrated in terms of progression-free survival in the ITT population (Table 7).
Antal patienter Progressionsfri overlevelse Median (måneder) Hazard ratio 
Number of patients Progression-free survival Median (months) Hazard ratio
(p-værdi = 0,0036) 
(p-value = 0.0036)
Effekten og sikkerheden af Avastin i frontlinjebehandling af patienter med epitelial ovariecancer, tubacancer eller primær peritonealcancer blev undersøgt i to fase III-studier (GOG-0218 og BO17707). 
The safety and efficacy of Avastin in the front-line treatment of patients with epithelial ovarian, fallopian tube or primary peritoneal cancer were studied in two phase III trials (GOG-0218 and BO17707) that evaluated the effect of the addition of Avastin to carboplatin and paclitaxel compared to the chemotherapy regimen alone.
Sepsis Abscesb,d Cellulitis Infektion Urinvejsinfektion 
Cellulitis, Infection, Urinary tract infection
Samlet overlevelse -Followupanalyse Hazard ratio (95% konfidensinterval) 
Overall survival - Follow-up analysis2 Hazard Ratio (95% CI)
Kemoterapi (n=144) 
CT (n=144)
Resultater fra studiet er opsummeret i tabel 20. 
The results of this study are summarised in Table 20.
(p-værdi = 0,0012) 
(p-value = 0.0012)
* Eksploratorisk analyse: endelig analyse af samlet overlevelse på klinisk cut-off 31. oktober 2017, hvor ca. 59 % af patienterne var døde. 
However two of the randomized patients discontinued the study before receiving any study treatment ^ Blinded independent review (protocol-defined primary analysis) * Exploratory analysis: final OS analysis at clinical cut off on 31 October 2017, approx. 59% of patients had died.
10 mg/kg hver 2. uge. 
b 10 mg/kg every 2 weeks.
Ovariesvigta,b 
Foetal abnormalitiesa,b
• træthed, 
• constipation,
Oral capecitabin to gange daglig i 2 uger (efterfulgt af 1 uge uden behandling) 
Oxaliplatin 130 mg/m2 IV 2 h Oxaliplatin on day 1 Capecitabine oral bid for 2 weeks (followed by 1 week off treatment)
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hvert hætteglas indeholder 400 mg bevacizumab. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains 400 mg bevacizumab.
• tarmblokade, 
• heart failure,
(12,0 vs 15,0 måneder; p = 0,6267) Primær-analyse blev udført ved data cut-off 12. december 2012 og betragtes som den endelige analyse 2 Followup-analyse blev udført ved data cut-off 7. marts 2014; p-værdier er kun vist for oplysende formål 
Follow-up analysis was performed with a data cut-off date of 07 March 2014; all p-values are displayed for descriptive purpose only
• GOG-0213 evaluerede bevacizumabs virkning og sikkerhed i kombination med carboplatin og paclitaxel, efterfulgt af bevacizumab som monoterapi, hos patienter med platinfølsom, recidiverende epitelial ovariecancer, tubacancer eller primær peritonealcancer. 
• GOG-0213 evaluated the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel, followed by bevacizumab as a single agent in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Tromboemboli (venøs)b,d 
Hypertensionb,d, Thrombo-embolism (venous)b,d
Hazard ratio (97,5 % konfidensinterval) 
Hazard ratio (97.5% CI)
Tromboemboli (arteriel)b,d Blødningb,d Dyb venetrombose 
Thromboembolism (arterial)b,d, Haemorrhageb,d,
Anæmi Lymfopeni 
Anaemia, Lymphopenia
Kongestivt hjertesvigtb,d Supraventrikulær takykardi 
Supraventricular tachycardia
Den anbefalede dosis af Avastin er 7,5 mg/kg eller 15 mg/kg legemsvægt en gang hver 3. uge administreret som intravenøs infusion. 
The recommended dose of Avastin is 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.
• blokering af vener i benene på grund af en blodprop, 
• blocking of the veins of the legs by a blood clot,
Median (måneder) Hazard ratio [95 % konfidensinterval] 
Median (months) Hazard ratio [95% CI]
Dysartri 
Lethargy
Den anbefalede dosis af Avastin er 10 mg/kg legemsvægt en gang hver 2. uge eller 15 mg/kg legemsvægt en gang hver 3. uge administreret som intravenøs infusion. 
The recommended dose of Avastin is 10 mg/kg of body weight given once every 2 weeks or 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.
Studiets primære effektparameter var varighed af samlet overlevelse. 
The primary efficacy variable of the trial was overall survival.
• CBP15+-arm: Fem serier af Avastin (15 mg/kg hver 3. uge startende i serie 2) i kombination med carboplatin (AUC 6) og paclitaxel (175 mg/m2) i 6 serier, efterfulgt af fortsat behandling med Avastin (15 mg/kg hver 3. uge) som monoterapi, i op til sammenlagt 15 måneders behandling. 
• CPB15+ arm: Five cycles of Avastin (15 mg/kg q3w started cycle 2) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m2) for 6 cycles followed by continued use of Avastin (15 mg/kg q3w) as single agent for a total of up to 15 months of therapy.
Pulmonal hypertensionc Næseseptumperforationc 
Pulmonary hypertensionc, Nasal septum perforationc
Intestinal perforation Ileus Intestinal obstruktion Rektovaginale fistlerc,dGastr ointestinale forstyrrelser Stomatitis Proktalgi 
Intestinal perforation, Ileus, Intestinal obstruction, Recto-vaginal fistulaec,d,
Cerebrovaskulære tilfælde Synkope Søvnighed Hovedpine 
Cerebrovascular accident, Syncope, Somnolence, Headache
Hazard ratio (95 % konfidensinterval) 2 p-værdi 
Hazard Ratio (95% CI) 2 p-value 3
Data for det sekundære endepunkt, den samlede overlevelse, er ikke tilgængelig endnu. 
The secondary endpoint of Overall Survival (OS) was not mature .
• åbent sår eller hul i slimhinderne i maven eller tyndtarmen (symptomer kan være mavesmerter, 
• an open sore or hole in the lining of the stomach or small intestine (the signs may include abdominal pain, feeling bloated, black tarry stools or blood in your stools (faeces) or blood in your vomit),
Patienter, som fik bevacizumab i en dosis på 15 mg/kg hver 3. uge i kombination med kemoterapi (carboplatin og paclitaxel) og fortsatte med at få bevacizumab-monoterapi (CPB15+), havde en klinisk betydningsfuld og statistisk signifikant forbedring af PFS sammenlignet med patienter, som blev behandlet med kemoterapi alene i frontlinjebehandlingsregimet. 
Compared to patients treated with chemotherapy (carboplatin and paclitaxel) alone in the front-line setting, patients who received bevacizumab at a dose of 15 mg/kg q3w in combination with chemotherapy and continued to receive bevacizumab alone (CPB15+), had a clinically meaningful and statistically significant improvement in PFS.
Median PFS (måneder) Hazard ratio (95 % konfidensinterval) Median OS (måneder) Hazard ratio (95 % konfidensinterval) Cervixcancer GOG-0240 Effekten og sikkerheden af Avastin i kombination med kemoterapi (paclitaxel og cisplatin eller paclitaxel og topotecan) i behandlingen af patienter med persisterende, recidiverende eller metastatisk cervixkarcinom blev evalueret i studiet GOG-0240, et randomiseret, 4-armet, åbent fase III multicenterstudie. 
The efficacy and safety of Avastin in combination with chemotherapy (paclitaxel and cisplatin or paclitaxel and topotecan) in the treatment for patients with persistent, recurrent or metastatic carcinoma of the cervix was evaluated in study GOG-0240, a randomised, four-arm, open label, multicentre phase III trial.
0,80 (p = 0,003) 95 % konfidensinterval (0,69-0,93) 
95% CI (0.69; 0.93)
Hos patienter, behandlet med Avastin for persisterende, recidiverende eller metastatisk cervixcancer, er tidligere strålebehandling en risikofaktor for gastrointestinal perforation og alle patienter, som fik gastrointestinal perforation, havde tidligere fået strålebehandling, 
Prior radiation is a risk factor for GI perforation in patients treated for persistent, recurrent or metastatic cervical cancer with Avastin and all patients with GI perforation had a history of prior radiation.
Censureret for NPT Median PFS (måneder) Hazard ratio konfidensinterval) p-værdi 
Censored for NPT Median PFS (months) Hazard ratio (95% CI) p -value
Studiet opfyldte det primære mål, som var forbedret samlet overlevelse. 
The trial met its primary objective of OS improvement.
Tal med din læge, hvis du har tilstande, som forårsager betændelse i maveregionen (f.eks. diverticulitis, mavesår, tyktarmsbetændelse forbundet med kemoterapi). 
If you have conditions causing inflammation inside the abdomen (e.g. diverticulitis, stomach ulcers, colitis associated with chemotherapy), please discuss this with your doctor.
Nasal septumperforation (ikke kendt) Pulmonal hypertension (ikke kendt) Dysfoni (almindelig) Mave-tarmkanalen Gastrointestinalt ulcus (ikke kendt) Lever og galdeveje Galdeblæreperforation (ikke kendt) Knogler, led, muskler og bindevæv 
Nasal septum perforation (not known) Pulmonary hypertension (not known) Dysphonia (common)
Tabel 2 indeholder også klinisk signifikante bivirkninger, som kun blev set post-marketing, og derfor kendes hverken frekvensen eller NCI-CTCAE-graden. 
These clinically significant adverse reactions were reported in clinical trials but the grade 3-5 reactions did not meet the threshold of at least a 2% difference compared to the control arm. Table 2 also includes clinically significant adverse reactions that were observed only in the postmarketing setting, therefore, the frequency and NCI-CTCAE grade is not known.These clinically significant reactions have therefore been included in Table 2 within the column entitled “Frequency Not Known.”
• hovedpine, 
• headache,
Ovariesvigt/fertilitet (se pkt. 
Ovarian failure/fertility (see sections 4.4 and 4.6)
• forstoppelse, 
• fatigue,
• Carboplatin (AUC4, dag 1) og gemcitabin (1.000 mg/m2 på dag 1 og 8) samtidig med Avastin (15 mg/kg, dag 1) hver 3. uge i 6 og op til 10 behandlingsserier, efterfulgt af Avastin (15 mg/kg hver 3. uge) som monoterapi indtil sygdomsprogresssion eller uacceptabel toksicitet. 
• CPB arm: Carboplatin (AUC5) and paclitaxel (175 mg/m2 IV) and concurrent Avastin (15 mg/kg) every 3 weeks for 6 and up to 8 cycles, followed by Avastin (15 mg/kg every 3 weeks) alone until disease progression or unacceptable toxicity.
Antal patienter Samlet overlevelse Median tid (måneder) 95 % konfidensinterval Hazard ratiob 
Number of patients Overall survival Median time (months) 95% CI Hazard ratiob
(p5<0,0001) 
(p-value5 <0.0001)
Metastatisk kolorektalkræft (mCRC) 
Metastatic carcinoma of the colon or rectum (mCRC)
Diarré Kvalme Opkastning Abdominalsmerter 
Diarrhoea, Nausea, Vomiting, Abdominal pain
Oxaliplatin 85 mg/m2 i.v. 
Oxaliplatin 85 mg/m2 IV 2 h Oxaliplatin on day 1 Leucovorin on day 1 and 2
● komparativ incidens, som er konstateret mellem behandlingsarme i kliniske studier (med mindst 10 % forskel i forhold til kontrolarmen for NCI-CTCAE grad 1-5 bivirkninger eller med mindst 2 % forskel i forhold til kontrolarmen for NCI-CTCAE grad 3-5 bivirkninger), 
difference compared to the control arm for NCI-CTCAE Grade 1-5 reactions or at least a 2%
Nedsat leverfunktion 
Investigations Weight decreased
Median PFS (måneder) 2 Hazard ratio [95 % konfidensinterval] 2 
Median PFS (months) Hazard ratio [95% CI] 2
Både bevacizumabdoser svarende til 5 mg/kg/uge og 2,5 mg/kg/uge viste statistisk signifikant fordel med hensyn til samlet overlevelse (hazard ratio 0,751 i E3200-studiet, hazard ratio 0,81 i ML18147studiet) og progressionfri overlevelse (hazard ratio 0,518 i E3200-studiet, hazard ratio 0,68 i ML18147-studiet). 
Both the 5 mg/kg/week and 2.5 mg/kg/week equivalent doses of bevacizumab provided a statistically significant benefit with regards to OS (HR 0.751 in study E3200;
Sårhelingskomplikationer (se pkt. 
Wound healing complications (see section 4.8)
4.8) Patienter kan have en øget risiko for gastrointestinal perforation og galdeblæreperforation, når de behandles med Avastin. 
Gastrointestinal (GI) perforations and Fistulae (see section 4.8) Patients may be at an increased risk for the development of gastrointestinal perforation and gall bladder perforation when treated with Avastin.
Letargi 
Myalgia
Idet maternel IgG udskilles i mælk, og da bevacizumab kan skade barnets vækst og udvikling (se pkt. 
As maternal IgG is excreted in milk and bevacizumab could harm infant growth and development (see section 5.3), women must discontinue breast-feeding during therapy and not breast-feed for at least six months following the last dose of Avastin.
Hypertensiv encefalopati (meget sjælden) (se også pkt. 
Hypertensive encephalopathy (very rare) (see also section 4.4 and Hypertension in section 4.8)
• blokering af vener på grund af en blodprop, 
• blocking of the veins by a blood clot,
BO17707 var et fase III, to-armet, multicenter, randomiseret, kontrolleret, åbent studie, som sammenlignede effekten af tillæg af Avastin til carboplatin plus paclitaxel hos patienter med FIGOstadie I eller IIA (grad 3 eller clear cell histologi alene, n = 142) eller FIGO-stadie IIB-IV (alle grader og alle histologiske typer, n =1.386) epitelial ovariecancer, tubacancer eller primær peritonealcancer efter operation (NCI-CTCAE v. 3). 
BO17707 was a Phase III, two arm, multicentre, randomised, controlled, open-label study comparing the effect of adding Avastin to carboplatin plus paclitaxel in patients with FIGO stage I or IIA (Grade
Median PFS (måneder) Hazard ratio (95 % konfidensinterval) Median OS (måneder) Hazard ratio (95 % konfidensinterval) Topotecan n=120 
Median PFS (months) Hazard ratio (95% CI) Median OS (months) Hazard ratio (95% CI)
Den anbefalede Avastindosis er 10 mg/kg kropsvægt en gang hver 2. uge som intravenøs infusion. 
The recommended dose of Avastin is 10 mg/kg of body weight given once every 2 weeks as an intravenous infusion.
Den anbefalede dosis af Avastin er 15 mg/kg kropsvægt en gang hver 3. uge som intravenøs infusion. 
The recommended dose of Avastin is 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.
Anoreksi Hypomagnesiæmi Hyponatriæmi 
Hypomagnesaemia Hyponatraemia
Median OS (måneder) Hazard ratio (95 % konfidensinterval) p-værdi 
Median OS (months) Hazard Ratio (95% CI) p-value
De fleste havde tidligere eller samtidigt fået behandling med intravenøse bisfosfonater, hvor osteonekrose af kæben er en kendt risiko. 
Cases of ONJ have been reported in cancer patients treated with Avastin, the majority of whom had received prior or concomitant treatment with intravenous bisphosphonates, for which ONJ is an identified risk.